Cytogen Announces Submission of IND for CYT-500 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer (RedNova)
PRINCETON, N.J., April 6 /PRNewswire-FirstCall/ -- Cytogen Corporation announced today the submission of an Investigational New Drug (IND) application to the U.S.

Spectral announces board and management appointments (SYS-CON Media)
Spectral Diagnostics Inc. (TSX: SDI), a developer of rapid diagnostic technologies, today announces the appointment of Mr. Edward E. McCormack to its Board of Directors. Mr. McCormack is an independent business consultant. From 1987 to 1999 he was the Senior Vice- President, Chief Financial Officer and a Director of Novopharm Limited, one of North America's largest generic pharmaceutical product